JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Search results for: '4 hqn'

Search results for: '4 hqn'

A2977 Cabozantinib (XL184, BMS-907351)

Summary: VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor

≥25.08 mg/mL
A8687 VX-702

Summary: P38α MAPK inhibitor,highly selective and ATP-competitive

insoluble in H2O; ≥20.2 mg/mL
BA2207 DHODH-IN-4

Summary: DHODH-IN-4 is an inhibitor of human and dihydroorotic acid dehydrogenase with values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively.
A3500 IRAK inhibitor 1
2 Citation

Target: IRAK

Summary: IRAK-4 inhibitor

insoluble in EtOH; insoluble in H2O; ≥14.4 mg/mL
A8216 PP 2 (AG 1879)
1 Citation

Summary: Src-family kinases inhibitor

insoluble in H2O; ≥15.1 mg/mL
A1980 SNS-032 (BMS-387032)
2 Citation

Target: Cyclin-Dependent Kinases

Summary: CDK inhibitor

insoluble in H2O; ≥19.05 mg/mL
A4329 Cilomilast

Target: Phosphodiesterases (PDEs)

Summary: Potent PDE4 inhibitor

insoluble in H2O; ≥12.95 mg/mL
BA7685 SWE101

Summary: SWE101 is a potent soluble epoxide hydrolase inhibitor with 4 μM and 2.8 μM against human and rat sEH-P, respectively.
BA8184 Dovramilast

Summary: Dovramilast (CC-11050) is a phosphodiesterase 4 inhibitor with oral activity that reduces the inflammatory response and improves mediated lung bacterial clearance.
A4034 Linagliptin (BI-1356)

Summary: DDP-4 inhibitor,highly potent and competitive

insoluble in H2O; insoluble in EtOH; ≥17.85 mg/mL